Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(1.87) by 87.7 percent. This is a 97.43 percent increase over losses of $(8.96) per share from the same period last year.